Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.64 |
| ▸ | CLK2 | P49760 | 1/20 | 0.64 |
| ▸ | BLK | P51451 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.64 |
| ▸ | STK3 | Q13188 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.64 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877535 | 0.85 | ROCK2 (0.77) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL1728904 | 0.85 | ROCK2 (0.64) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL1728902 | 0.85 | ROCK2 (0.64) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL3793015 | 0.85 | ROCK2 (0.64) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877970 | 0.85 | ROCK2 (0.76) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL3790618 | 0.84 | ROCK2 (0.72) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877958 | 0.83 | ROCK2 (0.73) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL1724078 | 0.83 | ROCK2 (0.72) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL1724986 | 0.83 | ROCK2 (0.72) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL1724076 | 0.83 | ROCK2 (0.72) | ROCK2ROCK1CLK2BLKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | KADMON CORPORATION, LLC | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.